Several studies suggest a decrease of Sfrp2 in a variety of cancers; further evidences indicate that Sfrp2 is able to inhibit the Wnt-induced increase in the levels of free β-catenin and influence inflammation and tumour cell proliferation [20,21]. This evidence concerns the gene SFRP2 and neoplasm.